{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:17:15Z","timestamp":1790615835134,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.inpsyc.2025.100182","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T04:47:34Z","timestamp":1767934054000},"page":"100182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of antidementia medicines on the dispensing of antidepressants, anxiolytics and antipsychotics"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-6199","authenticated-orcid":false,"given":"Osvaldo P.","family":"Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5148-0188","authenticated-orcid":false,"given":"Christopher","family":"Etherton-Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.inpsyc.2025.100182_bib1","doi-asserted-by":"crossref","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"Kales","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100182_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/S1041610204000468","article-title":"A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care","volume":"16","author":"Black","year":"2004","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.inpsyc.2025.100182_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.799723","article-title":"Clinical practice guidelines for the management of behavioral and psychological symptoms of dementia: a systematic review with AGREE II","volume":"13","author":"Ma","year":"2022","journal-title":"Front Neurol"},{"issue":"10","key":"10.1016\/j.inpsyc.2025.100182_bib4","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1002\/alz.14118","article-title":"Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: an up to 10-year follow-up study","volume":"20","author":"Xu","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.inpsyc.2025.100182_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jamaneurol.2023.1835","article-title":"Cholinesterase inhibitors for treatment of psychotic symptoms in Alzheimer disease and Parkinson disease: a meta-analysis","volume":"80","author":"d'Angremont","year":"2023","journal-title":"JAMA Neurol"},{"issue":"14","key":"10.1016\/j.inpsyc.2025.100182_bib6","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa066583","article-title":"Donepezil for the treatment of agitation in Alzheimer's disease","volume":"357","author":"Howard","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.inpsyc.2025.100182_bib7","first-page":"NG97","author":"National Institute for Health and Care Excellence","year":"2018","journal-title":"Dement Assess Manag Support People Living Dement their carers NICE"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100182_bib8","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1111\/jgs.19129","article-title":"Impact of federal antipsychotic use policy in nursing homes on new diagnoses for approved indications in dementia residents","volume":"72","author":"Shireman","year":"2024","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"10.1016\/j.inpsyc.2025.100182_bib9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/gps.5105","article-title":"Antidementia medication use by aged care facility residents with dementia","volume":"34","author":"Lind","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.inpsyc.2025.100182_bib10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","article-title":"The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers","volume":"8","author":"Mellish","year":"2015","journal-title":"BMC Res Notes"},{"issue":"10","key":"10.1016\/j.inpsyc.2025.100182_bib11","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s00415-019-09200-8","article-title":"Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis","volume":"266","author":"Jin","year":"2019","journal-title":"J Neurol"},{"issue":"9247","key":"10.1016\/j.inpsyc.2025.100182_bib12","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","article-title":"Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study","volume":"356","author":"McKeith","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100182_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/13872877251362202","article-title":"Validation of multiple linked administrative datasets to identify people with dementia","volume":"107","author":"Vu","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.inpsyc.2025.100182_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161092","article-title":"Differences of behavioral and psychological symptoms of dementia in disease severity in four major dementias","volume":"11","author":"Kazui","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.inpsyc.2025.100182_bib15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer's disease","volume":"366","author":"Howard","year":"2012","journal-title":"N Engl J Med"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104161022500420X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104161022500420X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:32:38Z","timestamp":1790613158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104161022500420X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S104161022500420X"],"URL":"https:\/\/doi.org\/10.1016\/j.inpsyc.2025.100182","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of antidementia medicines on the dispensing of antidepressants, anxiolytics and antipsychotics","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.inpsyc.2025.100182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Psychogeriatric Association.","name":"copyright","label":"Copyright"}],"article-number":"100182"}}